Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 12-Month Low – What’s Next?

Bicycle Therapeutics plc (NASDAQ:BCYC) shares reached a new 52-week low during trading on Monday . The stock traded as low as $8.96 and last traded at $8.96, with a volume of 158660 shares. The stock had previously closed at $9.08.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BCYC. JMP Securities dropped their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Stephens reissued an “equal weight” rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price target on shares of Bicycle Therapeutics in a report on Tuesday, March 11th. Finally, B. Riley dropped their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Stock Down 1.1 %

The stock has a market capitalization of $621.43 million, a PE ratio of -2.73 and a beta of 1.12. The company’s fifty day moving average price is $11.85 and its 200-day moving average price is $17.99.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. During the same period in the previous year, the company posted ($1.16) earnings per share. The company’s revenue for the quarter was down 30.2% compared to the same quarter last year. Equities research analysts anticipate that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, insider Santiago Arroyo sold 4,943 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $69,646.87. Following the completion of the transaction, the insider now owns 69,057 shares of the company’s stock, valued at approximately $973,013.13. The trade was a 6.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin Lee sold 9,038 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at approximately $6,974,916.34. The trade was a 1.79 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. boosted its stake in shares of Bicycle Therapeutics by 406.2% in the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company’s stock worth $63,769,000 after buying an additional 3,655,101 shares during the last quarter. Baker BROS. Advisors LP lifted its holdings in Bicycle Therapeutics by 15.8% in the fourth quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company’s stock valued at $152,395,000 after acquiring an additional 1,485,397 shares during the period. Fcpm Iii Services B.V. grew its stake in shares of Bicycle Therapeutics by 47.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company’s stock valued at $48,333,000 after purchasing an additional 1,112,369 shares during the period. Long Focus Capital Management LLC bought a new stake in shares of Bicycle Therapeutics during the 4th quarter valued at about $7,603,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Bicycle Therapeutics during the 3rd quarter valued at about $10,028,000. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.